<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[ViroPharma Inc. | Company News & Executive Profiles - VPHM | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/viropharma+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for ViroPharma Inc.]]></description>
	<s:counts start="0" returned="10" found="25" />
	<language>en-us</language>
	<item>
		<title><![CDATA[ViroPharma Incorporated Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-357998.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Yes. Operator instructions The first question we have is from Joel Sendek. Joel Sendek &#8211; Lazard Capital Markets Hi, thanks. Vin Milano Good morning, Joel. Joel Sendek &#8211; Lazard Capital Markets Good morning. Couple of questions. First of all, just some more details on the production of...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 28 Oct 2009 10:52:08 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/pcp.html"><![CDATA[PCP]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/viropharma+inc..html"><![CDATA[ViroPharma Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VPHM</category>
		<category domain="tickers">VPHM</category>
	</item>
	<item>
		<title><![CDATA[ViroPharma Finally Able to Look Forward]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F154327-viropharma-finally-able-to-look-forward%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: ViroPharma VPHM has lost a long-fought battle to keep generic versions of its top selling antibiotic,  Vancocin, off the market, a disappointing outcome for the company, but one that was widely anticipated. The antibiotic has been hugely profitable for ViroPharma and a few more years of...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 06 Aug 2009 08:45:12 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/viropharma+inc..html"><![CDATA[ViroPharma Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VPHM</category>
		<category domain="tickers">VPHM</category>
	</item>
	<item>
		<title><![CDATA[ViroPharma: FDA Issues Complete Response Letter for Cinryze]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F141421-viropharma-fda-issues-complete-response-letter-for-cinryze%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   By Jason Napodano, CFA On June 3, 2009, the U.S. FDA issued a complete response letter (CRL) relating to ViroPharma&#8217;s VPHM supplemental biologic license application sBLA on Cinryze for the treatment of acute attacks of hereditary angioedema (HAE). The CRL requests an additional clinical study, due...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 04 Jun 2009 12:24:21 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/viropharma+inc..html"><![CDATA[ViroPharma Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VPHM</category>
		<category domain="tickers">VPHM</category>
	</item>
	<item>
		<title><![CDATA[Buying ViroPharma Ahead of June 3rd FDA Decision]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F140056-buying-viropharma-ahead-of-june-3rd-fda-decision%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mark Cifra submits: Is it just me or does it seem like the good old days of biotech are back? With monster moves from Dendreon DNDN and Map Pharma MAPP based on positive phase 3 data, buyouts of IDM Pharma IDMI by Takeda and Cougar Biotech CGRB by [[JNJ]] and...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 28 May 2009 12:50:14 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mark+cifra.html"><![CDATA[Mark Cifra]]></category>
		<category domain="http://resources.bnet.com/topic/viropharma+inc..html"><![CDATA[ViroPharma Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VPHM</category>
		<category domain="tickers">VPHM</category>
	</item>
	<item>
		<title><![CDATA[ViroPharma Incorporated Q1 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-293095.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator  Operator Instructions Our first question comes from the line of John Newman with Oppenheimer.  John Newman - Oppenheimer  Thanks for taking the question. On Cinryze could you tell us what percentage of Cinryze patients currently on drug came from previous clinical trials including...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 29 Apr 2009 11:02:18 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/viropharma+inc..html"><![CDATA[ViroPharma Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VPHM</category>
		<category domain="tickers">VPHM</category>
	</item>
	<item>
		<title><![CDATA[ViroPharma, Inc., Q4 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-272454.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  Operator Instructions Our first question comes from the line Joel Sendek with Lazard Capital. Please proceed with your question. Joel Sendek - Lazard Capital Markets  Thanks. So, I just have a clarification question on Cinryze. So, I think you said you had some people on...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 24 Feb 2009 10:05:31 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/reimbursement.html"><![CDATA[Reimbursement]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/viropharma+inc..html"><![CDATA[ViroPharma Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VPHM</category>
		<category domain="tickers">VPHM</category>
	</item>
	<item>
		<title><![CDATA[Viropharma's Antiviral Bombs: Here We Go Again]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F119532-viropharma-s-antiviral-bombs-here-we-go-again%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  Viropharma VPHM has announced that their Phase III trial of maribavir, a compound targeting cytomegalovirus, failed big-time. Well, they didn't use the term "big-time", but they might as well have. The treatment group patients with recent bone marrow transplants showed no difference in CMV infection rates...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 10 Feb 2009 12:38:33 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/viropharma+inc..html"><![CDATA[ViroPharma Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VPHM</category>
		<category domain="tickers">VPHM</category>
	</item>
	<item>
		<title><![CDATA[Viropharma: Failed Bet on Orphan Drug]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F119635-viropharma-failed-bet-on-orphan-drug%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Donald Johnson submits: Bone marrow and organ transplant patients won't get help from Viropharma's VPHM new antiviral drug, maribavir, which failed its phase III trials. As a result VPHM plunged almost 53% yesterday to $5.74 a share. One analyst values it at $4 to $5. Key graphs from Reuters: ...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 10 Feb 2009 06:17:22 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/donald+johnson.html"><![CDATA[Donald Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/viropharma+inc..html"><![CDATA[ViroPharma Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VPHM</category>
		<category domain="tickers">VPHM</category>
	</item>
	<item>
		<title><![CDATA[Analysts Even More Bullish on ViroPharma]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F109213-analysts-even-more-bullish-on-viropharma%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   ViroPharma Inc. VPHM is seeing record sales of its big drug Vancocin which is adding to its already sizable cash hoard. Sales are expected to grow 159.26%. VPHM is an attractive value stock. ViroPharma is trading with a price-to-book of 1.44.  Company Description  ViroPharma...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 04 Dec 2008 05:43:20 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/viropharma+inc..html"><![CDATA[ViroPharma Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VPHM</category>
		<category domain="tickers">VPHM</category>
	</item>
	<item>
		<title><![CDATA[ViroPharma Incorporated Q3 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-244858.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  Operator instructions The first question is from May-Kin Ho from Goldman Sachs. Please proceed with your question. May-Kin Ho? Our next question is from Joel Sendek from Lazard Capital. Please proceed with your question. Joel Sendek &#8211; Lazard Capital Markets  Thanks. A couple of questions....]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 29 Oct 2008 11:19:12 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/enrollment.html"><![CDATA[Enrollment]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/question.html"><![CDATA[Question]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/enrollment.html"><![CDATA[Enrollment]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/question.html"><![CDATA[Question]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/viropharma+inc..html"><![CDATA[ViroPharma Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VPHM</category>
		<category domain="tickers">VPHM</category>
	</item>
</channel>
</rss>
